QURE Healthcare, San Francisco, CA, USA.
Aegis Sciences Corporation, Nashville, TN, USA.
Int J Clin Pract. 2022 Jul 30;2022:6450641. doi: 10.1155/2022/6450641. eCollection 2022.
Medication nonadherence in patients with chronic diseases is common, costly, and often underdiagnosed. In the United States, approximately 40-50% of patients with cardiometabolic conditions are not adherent to long-term medications. Drug-drug interactions (DDI) are also underrecognized and may lead to medication nonadherence in this patient population. Treatment complexity associated with cardiometabolic conditions contributes to increased risk for adverse drug events and DDIs.
We recruited a nationally representative sample of 246 board-certified family and internal medicine physicians to evaluate how they assessed, identified, and treated medication nonadherence, DDIs, and worsening disease. Participating physicians were asked to care for three online simulated patients, each with at least one chronic cardiometabolic disease, including atrial fibrillation, heart failure, diabetes mellitus, or hypertension, and who were taking prescription medications for their disease. Physicians' scores were based on evidence-based care recommendation criteria, including overall care quality and treatment for medication nonadherence and DDIs.
Overall, quality-of-care scores across all cases ranged from 13% to 87% with an average of 50.8% ± 12.1%. The average overall diagnostic plus treatment score was 21.9% ± 13.6%. Participants identified nonadherence in just 3.6% of cases, DDIs in 8.9% of cases, and disease progression in 30.3% of cases.
Based on these study results, primary care physicians were unable to adequately diagnose and treat patients with chronic cardiometabolic diseases who either suffered from medication nonadherence, DDIs, or progression of the disease. Improved standardization and technique in identifying these diagnoses is needed in primary care. . This trial is registered with clinicaltrials.gov, NCT05192590.
慢性病患者的药物不依从性很常见,代价高昂,且常常未被充分诊断。在美国,约有 40-50%的心血管代谢疾病患者不遵医嘱服用长期药物。药物-药物相互作用(DDI)也未被充分认识,可能导致该患者人群的药物不依从。与心血管代谢疾病相关的治疗复杂性增加了不良药物事件和 DDI 的风险。
我们招募了 246 名经过董事会认证的家庭和内科医生,组成一个具有全国代表性的样本,以评估他们如何评估、识别和治疗药物不依从、DDI 和病情恶化。参与研究的医生被要求照顾三名在线模拟患者,每位患者都患有至少一种慢性心血管代谢疾病,包括心房颤动、心力衰竭、糖尿病或高血压,并正在服用治疗疾病的处方药。医生的评分基于循证护理推荐标准,包括整体护理质量以及对药物不依从和 DDI 的治疗。
总体而言,所有病例的护理质量评分范围为 13%-87%,平均为 50.8%±12.1%。总体诊断加治疗评分的平均水平为 21.9%±13.6%。参与者仅在 3.6%的病例中识别出药物不依从,8.9%的病例中识别出 DDI,30.3%的病例中识别出疾病进展。
根据这些研究结果,初级保健医生无法充分诊断和治疗患有慢性心血管代谢疾病的患者,这些患者要么患有药物不依从,要么患有 DDI,要么疾病在进展。在初级保健中需要改进识别这些诊断的标准化和技术。这项试验在临床试验.gov 上注册,编号为 NCT05192590。